Obstetrics/Gynecology · Toms River, NJ
NPI
1407891609
Since 2006
Specialty
Obstetrics/Gynecology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
222 Oak Ave
Toms River, NJ, 08753
Phone (732) 914-1919
Groups this clinician bills Medicare through
Medicare paid, 2024
$57K
1,224 services
Medicare patients, 2024
552
Average age 72
Drug cost, 2024
$47K
508 prescriptions
Company payments, 2025
$366
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marie L Bonvicino was code G0101 (cervical or vaginal cancer screening; pelvic and clinical breast examination), 263 times for 263 patients. In total Marie L Bonvicino billed 1,224 services in 34 codes, and Medicare paid $57K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| G0101 Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 263 | 263 | $41.45 | $11K |
| 99459 Office/Outpatient Services | Office | 258 | 213 | $16.59 | $4,281 |
| 99213 Office E&M - Established | Office | 138 | 123 | $70.51 | $9,731 |
| 96127 Behavioral Health Services | Office | 105 | 105 | $3.30 | $346 |
| 99212 Office E&M - Established | Office | 98 | 78 | $41.36 | $4,053 |
| Q0091 Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 85 | 85 | $47.07 | $4,001 |
| 76830 Ultrasound - Abdomen and Pelvis | Office | 76 | 72 | $91.66 | $6,966 |
| 99214 Office E&M - Established | Office | 50 | 46 | $99.12 | $4,956 |
| 99203 Office E&M - New | Office | 40 | 40 | $89.34 | $3,573 |
| 99202 Office E&M - New | Office | 26 | 26 | $52.45 | $1,364 |
| 76856 Ultrasound - Abdomen and Pelvis | Office | 13 | 13 | $75.86 | $986 |
By year: 2022 $47K for 659 services; 2023 $43K for 666 services; 2024 $57K for 1,224 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marie L Bonvicino prescribed most often to Medicare patients was Estradiol, with 84 prescriptions and refills. In total Marie L Bonvicino wrote 508 Medicare prescriptions that cost $47K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Estradiol Generic | 84 | 185 | 47 | $5,870 |
| Alendronate Sodium Generic | 37 | 89 | Under 11 | $218 |
| Clobetasol Propionate Generic | 33 | 37 | 22 | $1,016 |
| Raloxifene Hcl Generic | 30 | 90 | 12 | $1,364 |
| Metronidazole Generic | 26 | 27 | 23 | $619 |
| Nystatin Generic | 23 | 25 | 20 | $215 |
| Misoprostol Generic | 21 | 21 | 19 | $35.91 |
| Fluconazole Generic | 21 | 21 | 20 | $105 |
| Terconazole Generic | 20 | 20 | 16 | $497 |
| Valacyclovir Valacyclovir Hcl | 20 | 46 | Under 11 | $526 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 18 | 18 | 17 | $149 |
| Veozah Fezolinetant | 18 | 42 | Under 11 | $22K |
| Triamcinolone Acetonide Generic | 17 | 23 | Under 11 | $85.8 |
| Clindamycin Phosphate Generic | 14 | 14 | 14 | $803 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 14 | 14 | 12 | $344 |
Brand drugs: 80 claims; generic drugs: 428 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marie L Bonvicino $366 ($366 in general payments such as food, travel and fees) from 11 companies. The largest payer was Astellas Pharma US Inc with $137.
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc 4503.T | 7 | $137 |
| Sage Therapeutics, LLC SAGE | 3 | $48.14 |
| Organon LLC OGN | 2 | $34.32 |
| Abbvie Inc. ABBV | 2 | $33.76 |
| Hologic Sales and Service, LLC HOLX | 1 | $19.39 |
| Millicent US Inc | 1 | $17.1 |
| Sumitomo Pharma America, Inc. 4506.T | 1 | $16.04 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. SUPN | 1 | $15.36 |
| CooperSurgical, Inc. COO | 1 | $14.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.